Skip to main content

Advertisement

Table 1 Characteristics of mCRPC patients included in this study

From: 3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT

  P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11
Age 66 68 47 61 73 63 82 83 79 67 88
Activity (GBq) 3.7 3.7 3.7 3.7 6.0 6.0 6.0 6.0 6.0 6.1 6.1
Cycle 1 1 1 1 1 1 1 5 1 1 1
Metastases (VIS = visceral, LYM = lymph, OSS = osseous) OSS Mainly VIS (liver), OSS, LYM Mainly OSS, LYM Mainly OSS, LYM Mainly OSS, LYM OSS, LYM Mainly OSS, LYM, VIS Mainly OSS, LYM, VIS Mainly OSS, LYM Mainly OSS, LYM OSS
Initial TNM classification and Gleason score pT4, N1, R1, G3, Gleason 8 pT3b, pN1, R0, G3, Gleason 9 pT3a, pN1, pR1, Gleason 9 pT3b, pN1, R1, Gleason 9 pT3b, pN1 T3a, N1 pT4, pN1, R1, G3, Gleason 9 pT4, pN1, R1, G3, Gleason 9 n.a. pT3, pN0, R1, Gleason 7 n.a.
PSA (ng/ml) prior to RLT 1201 368 408 5436 2311 0.86 65.7 65.6 418 20.6 52.1
Pre-therapies (1, yes/0, no)
▪ Surgery 1 0 1 1 1 1 1 1 1 1 0
▪ Radiotherapy 1 1 0 1 1 0 1 1 0 1 0
▪ Anti-hormonal therapy (including 2nd line anti-hormonal therapy with bicalutamide, enzalutamide, abiraterone acetate) 1 1 1 1 1 1 1 1 1 1 1
▪ Ra-223 1 0 1 0 0 0 0 0 0 1 0
▪ Chemotherapy (docetaxel, cabazitaxel) 1 1 1 1 1 1 0 0 1 1 0
Blood baseline            
▪ Leukocytes (G/l) 7.2 4.9 6 5.6 5.2 4.54 5.41 4.85 5.31 2.73 7.84
▪ Lymphocytes (G/l0 0.57 0.96 1.71 0.49 0.56 1.14 0.95 0.48 0.94 0.28 2.06
▪ Hemoglobin (g/dl) 14.1 12.3 12.8 9.6 10.9 13.3 10.5 8.4 10.5 8.3 12.1
▪ Thrombocytes (G/l) 195 307 323 291 235 227 450 305 223 89 281
▪ Erythrocytes (T/l) 4.79 4.31 4.36 4.08 3.86 4.11 3.96 3.25 3.55 3.2 3.64